Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | CA1 | P00915 | 8/20 | 0.52 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
| ▸ | CA12 | O43570 | 6/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA3 | P07451 | 3/20 | 0.52 |
| ▸ | CA4 | P22748 | 3/20 | 0.52 |
| ▸ | CA6 | P23280 | 3/20 | 0.52 |
| ▸ | CA5A | P35218 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653955 | 0.83 | F2 (0.37) | F2PRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL29395884 | 0.83 | F2 (0.54) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL5654389 | 0.81 | KMT2A (0.62) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL10494209 | 0.79 | F2 (0.63) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL10531766 | 0.78 | F2 (0.67) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL11007951 | 0.76 | ALDH1A1 (0.50) | CA2CA1CA9CA12ALDH1A1 | |
| SCHEMBL10864649 | 0.76 | LMNA (0.43) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL5654867 | 0.74 | VCAM1 (0.40) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL5655146 | 0.74 | F2 (0.52) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL22302 | 0.74 | F2 (0.52) | F2PRSS1PRSS2PRSS3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233943-B2 | Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-12 | — | — | US | claimed |
| US-20150011782-A1 | PROCESS FOR SYNTHESIS OF SYN AZIDO EPOXIDE AND ITS USE AS INTERMEDIATE FOR THE SYNTHESIS OF AMPRENAVIR & SAQUINAVIR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-01-08 | — | — | US | claimed |
| US-4310459-A | Process for producing carbamoyl substituted penams and carbamoyl substituted cephams from penicillin sulfoxide esters | BRISTOL-MYERS COMPANY (US) | 1982-01-12 | — | — | US | claimed |
| US-12615430-B2 | Neural network device and control method | Sony Group Corporation (JP) | 2026-04-28 | — | — | US | disclosed |
| US-12263590-B2 | Machine vision parsing of three-dimensional environments employing neural networks | SANCTUARY COGNITIVE SYSTEMS CORPORATION (CA) | 2025-04-01 | — | — | US | disclosed |
| US-20240414428-A1 | NEURAL NETWORK DEVICE, CONTROL METHOD, AND PROGRAM | Sony Group Corporation (JP) | 2024-12-12 | — | — | US | disclosed |
| WO-2023074414-A1 | NEURAL NETWORK DEVICE, CONTROL METHOD, AND PROGRAM | ソニーグループ株式会社 | 2023-05-04 | — | — | WO | disclosed |
| US-9233943-B2 | Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-12 | — | — | US | disclosed |
| US-20150011782-A1 | PROCESS FOR SYNTHESIS OF SYN AZIDO EPOXIDE AND ITS USE AS INTERMEDIATE FOR THE SYNTHESIS OF AMPRENAVIR & SAQUINAVIR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-01-08 | — | — | US | disclosed |
| WO-2013105118-A1 | A PROCESS FOR SYNTHESIS OF SYN AZIDO EPOXIDE AND ITS USE AS INTERMEDIATE THE SYNTHESIS OF AMPRENAVIR & SAQUINAVIR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-18 | — | — | WO | disclosed |
| US-7030274-B2 | Process for the production of carbodiimide modified organic isocyanates | BAYER MATERIALSCIENCE LLC (US) | 2006-04-18 | — | — | US | disclosed |
| EP-0132675-A2 | Preparations of polyisocynate containing reversibly blocked catalysts, process for their production, their use in the production of polyurethanes, and addition products of sulfonylisocyanates on catalysts with a structure of carboxylates of tin II or IV | BAYER AG (DE) | 1985-02-13 | — | — | EP | disclosed |
| US-4426520-A | CEPHALOSPORIN ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1984-01-17 | — | — | US | disclosed |
| US-4407755-A | BACTERICIDAL PENICILLINS | BRISTOL-MYERS COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| US-4374982-A | Cepham compounds | BRISTOL-MYERS COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4322347-A | 2-Carbamoyloxymethyl-penicillin derivatives | BRISTOL-MYERS COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| US-4310459-A | Process for producing carbamoyl substituted penams and carbamoyl substituted cephams from penicillin sulfoxide esters | BRISTOL-MYERS COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4113734-A | Masked isocyanates | AGFA-GEVAERT, N.V. (BE) | 1978-09-12 | — | — | US | disclosed |
| US-4073767-A | Hydrogen phosphonates and polymers containing them as flame retardants | MONSANTO COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
| US-3971740-A | DYES FOR POLYESTER FIBERS | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12615430-B2 | Neural network device and control method | NCDN, POU2F1, POU2F2 | F2 3911/4885PRSS1 2098/4885PRSS2 2323/4885 |
| US-20150011782-A1 | PROCESS FOR SYNTHESIS OF SYN AZIDO EPOXIDE AND ITS USE AS INTERMEDIATE FOR THE SYNTHESIS OF AMPRENAVIR & SAQUINAVIR | POR, CYP3A4, CYP2S1 | F2 950/4885PRSS1 249/4885PRSS2 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.